Clinical Trial
doi: 10.1002/1097-0142(196901)23:1<109::aid-cncr2820230112>3.0.co;2-1.
Clinical trial of delta-1-testololactone (NSC 23759), medroxy progesterone acetate (NSC 26386) and oxylone acetate (NSC 47438) in advanced female mammary cancer. A report of the cooperative breast cancer group
- PMID: 4884063
- DOI: 10.1002/1097-0142(196901)23:1<109::aid-cncr2820230112>3.0.co;2-1
Item in Clipboard
Clinical Trial
Clinical trial of delta-1-testololactone (NSC 23759), medroxy progesterone acetate (NSC 26386) and oxylone acetate (NSC 47438) in advanced female mammary cancer. A report of the cooperative breast cancer group
Cancer.
1969 Jan.
No abstract available
Similar articles
-
Comparison of 1 -testololactone (NSC-23759) and an estrogen-progestin combination (NSC-77622) in the treatment of metastatic breast cancer.Cancer Chemother Rep. 1970 Aug;54(4):249-53. Cancer Chemother Rep. 1970. PMID: 4946009 Clinical Trial. No abstract available.
-
High-dosage delta-1-testololactone therapy of disseminated carcinoma of the breast.Cancer. 1967 Mar;20(3):458-61. doi: 10.1002/1097-0142(1967)20:3<458::aid-cncr2820200314>3.0.co;2-u. Cancer. 1967. PMID: 6021501 No abstract available.
-
[Megestrol acetate versus medroxyprogesterone acetate in the treatment of metastasizing breast cancers. Intermediate report of a multicenter phase III study].Onkologie. 1987 Apr;10(2):104-6. doi: 10.1159/000216383. Onkologie. 1987. PMID: 2954006 Clinical Trial. German. No abstract available.
-
[Estrogen antagonists and inhibitors in hormone therapy of breast cancer].Vopr Onkol. 1989;35(7):771-8. Vopr Onkol. 1989. PMID: 2528239 Review. Russian. No abstract available.
-
Clinical significance of differences in bioavailability of medroxyprogesterone acetate preparations.Clin Pharmacokinet. 1989 Mar;16(3):129-33. doi: 10.2165/00003088-198916030-00001. Clin Pharmacokinet. 1989. PMID: 2524303 Review. No abstract available.
Cited by
-
Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes.Cancer Chemother Pharmacol. 1980;4(4):267-9. doi: 10.1007/BF00255272. Cancer Chemother Pharmacol. 1980. PMID: 7438329
-
High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy.Cancer Chemother Pharmacol. 1979;2(3):175-80. doi: 10.1007/BF00258291. Cancer Chemother Pharmacol. 1979. PMID: 455571 No abstract available.
-
Lack of correlations between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function, and tumour response in patients with advanced breast cancer.Cancer Chemother Pharmacol. 1985;14(2):112-5. doi: 10.1007/BF00434347. Cancer Chemother Pharmacol. 1985. PMID: 3156002
-
First generation aromatase inhibitors--aminoglutethimide and testololactone.Breast Cancer Res Treat. 1994;30(1):57-80. doi: 10.1007/BF00682741. Breast Cancer Res Treat. 1994. PMID: 7949205 Review.
-
A phase I/II study of high-dose megestrol acetate in the treatment of metastatic breast cancer.Breast Cancer Res Treat. 1991 Aug;18(3):171-7. doi: 10.1007/BF01990033. Breast Cancer Res Treat. 1991. PMID: 1756260 Clinical Trial.